Putting Patients First Healthcare Freedom Act

The Putting Patients First Healthcare Freedom Act (HR6512) was introduced on December 9, 2025 by Rep. Andy Biggs (R-AZ-5) with two cosponsors. The bill has been referred to four committees (Energy and Commerce, Ways and Means, Education and Workforce, Judiciary), indicating jurisdictional conflicts that slow progress. With only 3 sponsors and no Senate companion bill, the legislation is dead on arrival in its current form — it would require significant bipartisan support and committee markups to advance, neither of which is present. The bill's passage probability is low (<10% within the 119th Congress), but it serves as a policy marker for the Republican majority's stance on ACA subsidies. The money trail is straightforward: the bill does not authorize or appropriate any funding. Instead, it eliminates an existing expenditure — the enhanced ACA premium subsidies first introduced in the American Rescue Plan Act of 2021 and extended through the Inflation Reduction Act. These enhanced subsidies increased premium tax credits for individuals earning up to 400% of the federal poverty level and removed the income cap for subsidy eligibility. The Congressional Budget Office has scored prior extensions of these subsidies at roughly $25 billion per year in deficit spending. Eliminating them would save the federal government that amount but would transfer that cost directly to insurers through lower enrollment and higher uncompensated care. The structural winners under this bill are: (1) health insurers with minimal ACA exchange exposure — Cigna ($CI) has largely exited the ACA market; (2) uninsured-focused providers like community health centers and safety-net hospitals that would see increased demand; (3) medical debt collectors and hospital systems serving uncompensated care populations. The structural losers are insurers with high ACA exchange exposure: Centene ($CNC) is the most vulnerable (Ambetter is the #1 ACA plan in 20+ states representing 40-45% of its premium revenue), followed by Molina ($MOH), Humana ($HUM), and UnitedHealth ($UNH). Real market data as of April 30, 2026 shows a stark disconnect between legislative risk and market pricing. Over the past 30 days, $CNC has surged +64.02% from $38.17 to $53.70; $MOH is up +46.59% from $148.97 to $195.41; $HUM has gained +40.2% from $205.14 to $243.09; and $UNH has risen +36.08% from $324.63 to $368.22. These gains appear driven by other factors — strong Medicare Advantage enrollment, favorable CMS reimbursement rate updates, and overall market rotation into value/healthcare stocks — rather than any diminished legislative threat. The 7-day changes further confirm momentum: $CNC +28.41%, $HUM +12.94%, $MOH +11.07%, $UNH +3.75%. The legislative timeline: the bill has been in committee since December 2025 with no hearings or markups. For it to become law, it would need to pass through four committees, receive floor votes in both chambers, and be signed by the President. Enhanced ACA subsidies are set to expire at the end of 2025 (under current law), but Congress has extended them repeatedly — the legislative pattern is 'kicking the can' rather than repeal. The 2026 midterm elections create additional uncertainty: a change in House control would kill any subsidy rollback.